PF-06263276 / Pfizer - LARVOL DELTA

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Pfizer; Trial primary completion date: Oct 2014 ->Feb 2015

Trial primary completion date • Biosimilar • Immunology • Inflammation • Psoriasis

Pfizer pipeline (Pfizer Press Release) - PF-06263276: New molecule in P1 for Psoriasis.

New molecule • Immunology

Design and Synthesis of a pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. (PubMed) - J Med Chem - "Using a structure-based computational method for identification of structurally novel JAK inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in PF-06263276 (2) which was advanced into clinical studies."

Journal • Biosimilar